Table 2.
Comparisons of Long-Term Oncologic Outcomes
| Variables (N [%]) | Total (N=549) | IBR (N=93) | CBR (N=456) | P |
|---|---|---|---|---|
| Period of follow-up, months* | 47.8±27.3 | 27.7±25.6 | 51.9±25.8 | < 0.001 |
| Postoperative adjuvant TACE | 171 (31.1) | 29 (31.2) | 142 (31.1) | 1.000 |
| Recurrence during the follow-up | 348 (63.4) | 91 (97.8) | 257 (56.4) | < 0.001 |
| Early recurrence (within 2 years) | 237 (43.2) | 86 (92.5) | 152 (33.3) | < 0.001 |
| Later recurrence (beyond 2 years)** | 111 (36.4) | 5 (62.5) | 105 (35.3) | < 0.001 |
| Patterns of initial recurrence | ||||
| Intrahepatic recurrence | 277 (50.5) | 70 (75.3) | 207 (45.4) | < 0.001 |
| Extrahepatic recurrence | 18 (3.3) | 7 (7.5) | 11 (2.4) | 0.012 |
| Intra- and Extrahepatic recurrence | 53 (9.7) | 14 (15.1) | 39 (8.6) | 0.080 |
| Mortality during the follow-up | 290 (52.8) | 75 (80.6) | 215 (47.1) | < 0.001 |
| Cancer-specific mortality | 235 (42.8) | 69 (74.2) | 166 (36.4) | < 0.001 |
| Non-cancer-specific mortality | 55 (10.0) | 6 (6.5) | 49 (10.7) | 0.257 |
| Median OS, 95% CI, months | 65.6 (55.4~75.8) | 18.2 (12.8~23.6) | 77.9 (65.4~90.4) | < 0.001 |
| 1-year OS rate, % | 92.2 | 73.0 | 96.0 | |
| 3-year OS rate, % | 66.5 | 26.6 | 74.3 | |
| 5-year OS rate, % | 53.9 | 19.9 | 60.7 | |
| Median RFS, 95% CI, months | 33.5 (26.9~40.1) | 6.1 (5.1~7.1) | 47.5 (37.5~57.5) | < 0.001 |
| 1-year RFS rate, % | 70.7 | 20.4 | 80.9 | |
| 3-year RFS rate, % | 47.2 | 5.4 | 55.7 | |
| 5-year RFS rate, % | 37.4 | 2.9 | 44.5 |
Notes: *Values are mean ± standard deviation. **Numbers of patients who were disease-free alive at 2 years of surgery were 305, 8, and 297 in the overall, IBR, and CBR cohorts, respectively.
Abbreviations: CI, confidence interval; OS, overall survival; RFS, recurrence-free survival; TTR, time-to-recurrence; IBR, incomplete biomarker response; CBR, complete biomarker response; TACE, transcatheter arterial chemoembolization.